Cargando…

The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department

AIMS: When relying on clinical assessment alone, an estimated 22% of acute heart failure (AHF) patients are missed, so clinical guidelines recommend the use of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for AHF diagnosis. Since publication of these guidelines, there has been poor uptake o...

Descripción completa

Detalles Bibliográficos
Autores principales: Walkley, Ryan, Allen, A. Joy, Cowie, Martin R., Maconachie, Ross, Anderson, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682884/
https://www.ncbi.nlm.nih.gov/pubmed/37697738
http://dx.doi.org/10.1002/ehf2.14471
_version_ 1785151073711816704
author Walkley, Ryan
Allen, A. Joy
Cowie, Martin R.
Maconachie, Ross
Anderson, Lisa
author_facet Walkley, Ryan
Allen, A. Joy
Cowie, Martin R.
Maconachie, Ross
Anderson, Lisa
author_sort Walkley, Ryan
collection PubMed
description AIMS: When relying on clinical assessment alone, an estimated 22% of acute heart failure (AHF) patients are missed, so clinical guidelines recommend the use of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for AHF diagnosis. Since publication of these guidelines, there has been poor uptake of NT‐proBNP testing in part due to concerns over excessive false positive referrals resulting from the low specificity of a single ‘rule‐out’ threshold of <300 pg/mL. Low specificity can be mitigated by the addition of age‐specific ‘rule‐in’ NT‐proBNP thresholds. METHODS AND RESULTS: A theoretical hybrid decision tree/semi‐Markov model was developed, combining global trial and audit data to evaluate the cost‐effectiveness of NT‐proBNP testing using age‐specific rule‐in/rule‐out (RI/RO) thresholds, compared with NT‐proBNP RO only and with clinical decision alone (CDA). Cost‐effectiveness was measured as the incremental cost per quality‐adjusted life year (QALY) gained and incremental net health benefit. In the base case, using UK‐specific inputs, NT‐proBNP RI/RO was associated with both greater QALYs and lower costs than CDA. At a willingness‐to‐pay threshold of £20 000/QALY, NT‐proBNP RO was also cost‐effective compared with CDA [incremental cost‐effectiveness ratio (ICER) of £8322/QALY], but not cost‐effective vs. RI/RO (ICER of £64 518/QALY). Overall, NT‐proBNP RI/RO was the most cost‐effective strategy. Sensitivity and scenario analyses were undertaken; the conclusions were not impacted by plausible variations in parameters, and similar conclusions were obtained for the Netherlands and Spain. CONCLUSIONS: An NT‐proBNP strategy that combines an RO threshold with age‐specific RI thresholds provides a cost‐effective alternative to the currently recommended NT‐proBNP RO only strategy, achieving greater diagnostic specificity with minimal reduction in sensitivity and thus reducing unnecessary echocardiograms and hospital admissions.
format Online
Article
Text
id pubmed-10682884
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106828842023-11-30 The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department Walkley, Ryan Allen, A. Joy Cowie, Martin R. Maconachie, Ross Anderson, Lisa ESC Heart Fail Original Articles AIMS: When relying on clinical assessment alone, an estimated 22% of acute heart failure (AHF) patients are missed, so clinical guidelines recommend the use of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for AHF diagnosis. Since publication of these guidelines, there has been poor uptake of NT‐proBNP testing in part due to concerns over excessive false positive referrals resulting from the low specificity of a single ‘rule‐out’ threshold of <300 pg/mL. Low specificity can be mitigated by the addition of age‐specific ‘rule‐in’ NT‐proBNP thresholds. METHODS AND RESULTS: A theoretical hybrid decision tree/semi‐Markov model was developed, combining global trial and audit data to evaluate the cost‐effectiveness of NT‐proBNP testing using age‐specific rule‐in/rule‐out (RI/RO) thresholds, compared with NT‐proBNP RO only and with clinical decision alone (CDA). Cost‐effectiveness was measured as the incremental cost per quality‐adjusted life year (QALY) gained and incremental net health benefit. In the base case, using UK‐specific inputs, NT‐proBNP RI/RO was associated with both greater QALYs and lower costs than CDA. At a willingness‐to‐pay threshold of £20 000/QALY, NT‐proBNP RO was also cost‐effective compared with CDA [incremental cost‐effectiveness ratio (ICER) of £8322/QALY], but not cost‐effective vs. RI/RO (ICER of £64 518/QALY). Overall, NT‐proBNP RI/RO was the most cost‐effective strategy. Sensitivity and scenario analyses were undertaken; the conclusions were not impacted by plausible variations in parameters, and similar conclusions were obtained for the Netherlands and Spain. CONCLUSIONS: An NT‐proBNP strategy that combines an RO threshold with age‐specific RI thresholds provides a cost‐effective alternative to the currently recommended NT‐proBNP RO only strategy, achieving greater diagnostic specificity with minimal reduction in sensitivity and thus reducing unnecessary echocardiograms and hospital admissions. John Wiley and Sons Inc. 2023-09-11 /pmc/articles/PMC10682884/ /pubmed/37697738 http://dx.doi.org/10.1002/ehf2.14471 Text en © 2023 Roche Diagnostics Ltd and The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Walkley, Ryan
Allen, A. Joy
Cowie, Martin R.
Maconachie, Ross
Anderson, Lisa
The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title_full The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title_fullStr The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title_full_unstemmed The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title_short The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department
title_sort cost‐effectiveness of nt‐probnp for assessment of suspected acute heart failure in the emergency department
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682884/
https://www.ncbi.nlm.nih.gov/pubmed/37697738
http://dx.doi.org/10.1002/ehf2.14471
work_keys_str_mv AT walkleyryan thecosteffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT allenajoy thecosteffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT cowiemartinr thecosteffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT maconachieross thecosteffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT andersonlisa thecosteffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT walkleyryan costeffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT allenajoy costeffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT cowiemartinr costeffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT maconachieross costeffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment
AT andersonlisa costeffectivenessofntprobnpforassessmentofsuspectedacuteheartfailureintheemergencydepartment